KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial.

Ruo-Xi Hong, Fei Xu, Wen Xia, Yue-E Teng, Qu-Chang Ouyang, Qiu-Fan Zheng, Zhong-Yu Yuan, Dong-Shao Chen, Kui-Kui Jiang, Ying Lin, Zhen Dai, Xin-Lan Liu, Qian-Jun Chen, Xin-Hong Wu, Yan-Xia Shi, Jia-Jia Huang, Xin An, Cong Xue, Xi-Wen Bi, Mei-Ting Chen, Hui Li, He-Rui Yao, Guo-Rong Zou, Heng Huang, Jing-Min Zhang, Shu-Sen Wang

J Clin Oncol 43(11) 1314-1324

PMID39746176
PMCIDPMC11974638
DOI10.1200/JCO.24.00938
发表日期2025-01-02
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: The effects of metronomic chemotherapy plus endocrine therapy have yet to be elucidated through a randomized phase III clinical trial. METHODS: Randomized clinical trials were conducted at 12 centers in China from August 22, 2017, to September 24, 2021, and the final follow-up date was August 25, 2023. Patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) who had no previous systemic therapy in the metastatic setting were enrolled. Participants were 1:1 assigned to receive either metronomic capecitabine plus an aromatase inhibitor (AI) or AI alone. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), objective response rate, disease control rate (defined as disease controlled for ≥24 weeks), and safety. RESULTS: A total of 263 patients were randomly assigned, among which 254 patients formed the full analysis set. At the median follow-up time of 50.7 months, 203 PFS events occurred. The metronomic capecitabine plus AI arm exhibited a median PFS of 20.9 months compared with 11.9 months in the AI arm (hazard ratio [HR], 0.58 [95% CI, 0.43 to 0.76]). The median OS was not reached in the combination arm and was 45.1 months in the AI arm (HR, 0.58 [95% CI, 0.37 to 0.93]). The most common adverse events were palmar-plantar erythrodysesthesia and peripheral neuropathy; grade 3 events occurred in 15.1% of the patients receiving combination treatment. CONCLUSION: The MECCA trial demonstrated a significant improvement in PFS and OS with first-line metronomic capecitabine plus AI compared with AI alone in patients with hormone receptor-positive+/HER2-negative MBC. Both treatment arms exhibited tolerable safety profiles consistent with previous reports.

KM 提取结果

3 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure1 个面板

FIG 2.

FIG 2. Kaplan-Meier estimates of PFS in 254 patients with hormone receptor–positive, HER2-negative metastatic breast cancer. AI, aromatase inhibitor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PFS, progression-free survival.

PFS

PFS

FIG 2. · Panel PFS

running 待 EXE 对齐 预期 2 条 已提取 2 条

Panel PFS 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

FIG 3.

FIG 3. Kaplan-Meier estimates of OS in 254 patients with hormone receptor–positive, HER2-negative metastatic breast cancer. AI, aromatase inhibitor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; OS, overall survival.

OS

OS

FIG 3. · Panel OS

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel OS 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:flat topline artifact
查看结果
KM Figure1 个面板

FIG A1.

FIG A1. Kaplan-Meier estimates of PFS in patients with hormone receptor–positive, HER2-negative metastatic breast cancer excluding those who received AI in the adjuvant setting. AI, aromatase inhibitor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PFS, progression-free survival.

Kaplan-Meier_estimates_of_PFS

PFS

FIG A1. · Panel Kaplan-Meier_estimates_of_PFS

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Kaplan-Meier_estimates_of_PFS 是同一 FIG A1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. CONSORT diagram. AI, aromatase inhibitor.
非 KM Figure
FIG 4.FIG 4. Subgroup analysis of progression-free survival in 254 patients with hormone receptor–positive, HER2-negative metastatic breast cancer. AI, aromatase inhibitor; ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; SERM, selective estrogen receptor modulator.
非 KM Figure